Literature DB >> 1391125

Secondary acute lymphoblastic leukemia with t (4;11): report on two cases and review of the literature.

E Auxenfants1, P Morel, J L Lai, C Sartiaux, L Detourmignies, F Bauters, P Fenaux.   

Abstract

We report two cases of secondary acute lymphoblastic leukemia (ALL) with t (4;11) (q21;q23) translocation occurring after chemotherapy and radiotherapy for a prior cancer. Seven previously published cases of secondary ALL with t (4;11) (q21;q23) are also reviewed. Most patients had received a combination of topoisomerase II inhibitors (anthracyclines, mitoxantrone, or the epipodophillotoxin derivatives VP16 or VM26) and cyclophosphamide, which have also been implicated in the pathogenesis of secondary acute myeloid leukemia (AML) with 11q23 rearrangements. These observations give further support to the existence of a subgroup of secondary acute leukemias with cytogenetic findings "specific" for de novo ALL and AML, especially those with translocations involving the 11q23 region.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1391125     DOI: 10.1007/bf01695815

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  31 in total

1.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Authors:  S Ziemin-van der Poel; N R McCabe; H J Gill; R Espinosa; Y Patel; A Harden; P Rubinelli; S D Smith; M M LeBeau; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Heterogeneity of human B lymphocytes as revealed by monoclonal antibodies.

Authors:  J Brochier; J P Magaud; G Cordier; I Millet; J Marti; P A Bryon
Journal:  Ann Immunol (Paris)       Date:  1984 Nov-Dec

3.  Characterization of the blast cells in acute leukemia with translocation (4;11): report of eight additional cases and of one case with a variant translocation.

Authors:  A Hagemeijer; J J van Dongen; R M Slater; M B van't Veer; H Behrendt; K Hählen; W Sizoo; J Abels
Journal:  Leukemia       Date:  1987-01       Impact factor: 11.528

4.  Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases.

Authors:  P Fenaux; J L Laï; I Quiquandon; C Preudhomme; B Dupriez; T Facon; C Lorthois; D Lucidarme; F Bauters
Journal:  Leuk Lymphoma       Date:  1991

5.  Acute lymphoblastic leukemia with t(4;11) translocation after osteogenic sarcoma.

Authors:  J Kapelushnik; I Dubé; P Wilson; M Greenberg
Journal:  Cancer       Date:  1991-06-01       Impact factor: 6.860

Review 6.  Two different classes of therapy-related and de-novo acute myeloid leukemia?

Authors:  J Pedersen-Bjergaard; P Philip
Journal:  Cancer Genet Cytogenet       Date:  1991-08

7.  The (4;11) translocation in acute leukaemia of childhood: the importance of additional chromosomal aberrations.

Authors:  L M Secker-Walker; E L Stewart; L Chan; U O'Callaghan; J M Chessells
Journal:  Br J Haematol       Date:  1985-09       Impact factor: 6.998

8.  4;11 translocation-associated acute leukemia: a comprehensive analysis.

Authors:  M De Braekeleer; C C Lin
Journal:  Cancer Genet Cytogenet       Date:  1986-03-01

9.  Acute leukemia with chromosome translocation (4;11): 7 new patients and analysis of 71 cases.

Authors:  F Lampert; J Harbott; W D Ludwig; C R Bartram; J Ritter; V Gerein; M Neidhardt; R Mertens; N Graf; H Riehm
Journal:  Blut       Date:  1987-06

10.  Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases.

Authors:  C H Pui; L S Frankel; A J Carroll; S C Raimondi; J J Shuster; D R Head; W M Crist; V J Land; D J Pullen; C P Steuber
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113

View more
  1 in total

Review 1.  Pharmacodynamics and long-term toxicity of etoposide.

Authors:  K Kobayashi; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.